Evidence map›Paper›PMID 41576297›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

Hong-Fei Gao, Guo-Lin Ye, Ying Lin, Qin Huang, Jie Dong, Yin Cao, Yan-Xia Zhao, Qian-Jun Chen, Shi-Hui Ma, Jie Ouyang and 21 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Observational
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Hong-Fei GaoDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Guo-Lin YeDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Ying LinBreast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID 0000-0002-5923-3306
Qin HuangDiagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China.
Jie DongDepartment of Breast Surgery, Guilin Municipal Hospital of Traditional Chinese Medicine, Guilin, China.
Yin CaoBreast Center, Dongguan People's Hospital, Dongguan, China.
Yan-Xia ZhaoDepatment of Medical Breast Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qian-Jun ChenState Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Shi-Hui MaBreast Central Region 1, Zhongshan City People's Hospital, Zhongshan, China.
Jie OuyangDepartment of Breast Surgery, Dongguan Tungwah Hospital, Dongguan, China.
Jin-Hui YeBreast Oncology Department, The First People's Hospital of Zhaoqing, Zhaoqing, Guangdong, China.
Hua-Wei YangBreast Surgery, Guangxi Medical University Cancer Hospital and Guangxi Cancer Institute, Guangxi Cancer Hospital and Medical University Oncology School and Cancer Center, Nanning, China.
Yuan-Qi ZhangBreast Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yong-Cheng ZhangThe First Affiliated Hospital/The First Clinical Medicine School of Guangdong Pharmaceutical University, Guangzhou, China.
Gang-Ling ZhangBreast Center, Baotou Cancer Hospital, Baotou, China.ORCID 0000-0002-1336-1265
Wei LiDepartment of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
Yunjian ZhangBreast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID 0000-0001-8457-8421
Zhi-Yong WuDiagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China.
Ying-Yi LinSchool of Medicine, South China University of Technology, Guangzhou, China.
Teng ZhuDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Liu-Lu ZhangDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Ci-Qiu YangDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Mei YangDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Hao PengDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.ORCID 0000-0002-6903-7325
Bo ChenDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Yi-Tian ChenDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Fei JiDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Min-Yi ChengDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Jie-Qing LiDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Zefei JiangSenior Department of Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China.ORCID 0000-0002-4127-2542
Kun WangDepartment of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.ORCID 0000-0001-9851-7080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe neoCARHP aimed to investigate the efficacy and safety of investigator-selected taxane (docetaxel, paclitaxel, or nab-paclitaxel) plus trastuzumab and pertuzumab, with carboplatin (TCbHP) or without carboplatin (THP), in stage II and III human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

methodsThe neoCARHP was a multicenter, randomized, phase III, noninferiority study. Eligible patients were women age 18 years or older with previously untreated, stage II and III, HER2-positive invasive breast cancer. Patients were randomly assigned (1:1) to receive six 3-week cycles of TCbHP or THP. The primary end point was pathologic complete response (pCR) rate in the breast and axilla (ypT0/is ypN0) in the modified intention-to-treat (mITT) population (all randomly assigned patients receiving at least one dose of study treatment). Safety was evaluated in all patients who received any study treatment.

resultsBetween April 30, 2021, and August 27, 2024, 774 patients were randomly assigned and 766 were included in the mITT population (382 in THP and 384 in TCbHP). pCR was achieved in 245 (64.1% [95% CI, 59.1 to 69.0]) patients in the THP group and 253 (65.9% [60.9-70.6]) in the TCbHP group (absolute difference, -1.8% [95% CI, -8.5 to 5.0]; odds ratio, 0.93 [95% CI, 0.69 to 1.25];

conclusionTHP provided noninferior pCR rates and improved tolerability compared with TCbHP. Omitting carboplatin may be applicable in HER2-positive breast cancer.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarboplatinErb-b2 Receptor Tyrosine KinasesTaxoidsTrastuzumabAdultAgedBridged-Ring CompoundsFemaleHumansMiddle AgedNeoadjuvant TherapyPaclitaxelPathologic Complete ResponseAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsCarboplatinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelpertuzumabTaxoidsTrastuzumab

Identifiers

PMID41576297
PMCPMC13258097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.